| 摘要 |
1326528 Contraceptive RICHARDSONMERRELL INC 20 Sept 1971 [5 Oct 1970] 43764/71 Heading A5B Contraception in human females is achieved by the administration of a progestagen (A) and an estrogen antagonising compound (B). They may be administered daily or the compound (A) may be administered at least during some of the days 5 to 28 of the menstrual cycle, compound (B) being administered on at least some of days 10 to 25. Suitable progestagens are: chlormadinone, megestrol acetate, melengestrol acetate, norethindrone and its acetate, norgestrel and its acetate, quingestanol and its acetate, desoxynorethindrone and ethynodiol diacetate. The estrogen antagonising agent is selected from the following (the quantities in parenthesis being the daily dose range): cisclomiphene (0.5-50 mg), 2-[p-(p-methoxy-α- phenylphenethyl) phenoxy]-triethylamine (10- 1000 mg), 1-[2-[p-(α-[p-methoxyphenyl]-#-nitrostyryl) phenoxy] ethyl] pyrrolidine (1 to 100 mg), 2[p-(1, 2-diphenyl-1-butenyl) phenoxy]-N, N-dimethylethylamine (1-100 mg), 2-[p-(1, 2- diphenyl-1-butenyl) phenoxy]-N, N-dimethylethylamine-antiestrogenic isomer (1-100 mg), 2-'[p-(6-methoxy-2-phenylindene - 3 - yl) phenoxy] ethyl pyrrolidine (2-200 mg), dl-13-ethylhydro- 6 -methoxy- 2 -phenyl-1-naphthyl) phenoxy] ethyl] pyrrolidine (2-200 mg), dl-3-ethylgona-1, 3, 5 (10)-triene-3, 16α, 17# triol (1- 100 mg) and compounds of the formula: wherein R is H or COCH 3 and R' is H or CH 3 , and equivalent quantities of pharmaceutically acceptable salts of the base compounds. |
